ACADIA Pharmaceuticals Inc. vs Best Buy Co Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Best Buy Co Inc trades at $84.02 (market cap $17.55B). The key difference: Best Buy Co Inc is far larger — about 3.5× ACADIA Pharmaceuticals Inc.'s market cap, and Best Buy Co Inc pays a 4.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBY | |
|---|---|---|
Market Cap | $5.07B | $17.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $90.17 |
52-Week Low | $20.06 | $55.52 |
Enterprise Value | $4.19B | $19.93B |
Dividend Yield | — | 4.61% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →